Altasciences has opened Algorithme Pharma USA, further expanding the company’s North American footprint and ability to provide comprehensive bioequivalence and phase I/IIa clinical drug development capabilities in the U.S.

Based in Fargo, N.D., Algorithme Pharma USA will focus on conducting bioequivalence  and bioavailability trials and will represent an extension of Algorithme Pharma, an Altasciences full-service, early stage, clinical CRO in Montreal, Canada. Clients will benefit from a full-range of support services including bioanalysis, data management, biostatistics, regulatory support, clinical pharmacology and project management. 

“Based on feedback from our U.S. client base, it has been an objective of ours to expand into the U.S. to provide additional options for accelerated study start-ups, studies with controlled substances and studies requiring more than one clinical site,” said Chris Perkin, CEO. “The site in Fargo provides us with a unique opportunity to leverage the expertise of a highly qualified team that matches Altasciences’ philosophy of offering excellence in customer service and the best quality early stage clinical development services.”